Research Topics
| E J FreireichSummaryAffiliation: The University of Texas Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Min Chiu Li: a perspective in cancer therapyEmil J Freireich
Adult Leukemia Research Program, Special Medical Education Programs, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 8:2764-5. 2002- Metastasis--an alternative hypothesisEmil J Freireich
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 103:1537-9. 2005..Perhaps most important, there is a need to devise therapeutic strategies that would treat cancer as a systemic illness and hopefully have a substantial impact on overall cancer mortality... - The investigational new drug application--who benefits?Emil J Freireich
Special Medical Education Programs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Nat Clin Pract Oncol 3:62-3. 2006 - Origins of platelet transfusion therapyEmil J Freireich
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Transfus Med Rev 25:252-6. 2011..Platelet replacement for thrombocytopenia prevents the hemorrhagic diathesis and has been universally practiced for over 50 years... - Should terminally ill patients have the right to take drugs that pass phase I testing? YesEmil J Freireich
Special Medical Education Programs, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
BMJ 335:478. 2007 - Leukocyte transfusion and the development of the continuous-flow blood cell separatorEmil J Freireich
The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 55, Houston, TX 77030, USA
Transfus Med Rev 25:344-50. 2011..Thus, the continuous-flow centrifugal blood cell separator has become an important instrument in the science of blood collection and transfusion... - Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survivalF J Giles
Departments of Leukemia, Biostatistics, and Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 61, Houston, TX 77030, USA
Leuk Lymphoma 42:67-73. 2001.... - Terminal deoxynucleotidyl transferase expression in acute myelogenous leukemia and myelodysplasia as determined by flow cytometryY O Huh
Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
Leuk Lymphoma 37:319-31. 2000..Among patients with a flow TdT% > 5%, those with a higher TdT intensity survived longer than those with a lower intensity. These data suggest that quantitative TdT measurement may contribute to prognostic estimate in AML patients... - Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemiaApostolia Maria Tsimberidou
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:1370-8. 2008..In the current study, the authors addressed this question by matching MS patients with analogous AML patients and comparing their clinical outcomes... - Impact of high-dose granulocyte transfusions in patients with cancer with candidemia: retrospective case-control analysis of 491 episodes of Candida species bloodstream infectionsAmar Safdar
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 101:2859-65. 2004..The authors sought to determine the impact of high-dose (approximately 5.5 x 10(10) cells) GTX in patients with candidemia... - Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer CenterApostolia M Tsimberidou
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 25:4648-56. 2007..We assessed whether characteristics of patients with CLL and SLL differ in ways other than the absolute lymphocyte count (ALC) and evaluated treatment outcomes and prognostic factors... - Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantationApostolia Maria Tsimberidou
Department of Leukemia, Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
J Clin Oncol 24:2343-51. 2006..The purpose of this study was to assess the incidence, presenting characteristics, and treatment outcomes of Richter's syndrome (RS) and factors predicting response and survival... - Eradication of minimal residual disease in hairy cell leukemiaFarhad Ravandi
Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 107:4658-62. 2006..Disease characteristics may potentially be used to identify patients that are more likely to benefit from such additional therapy... - Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusionsAmar Safdar
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:2664-71. 2006..The authors evaluated the safety and efficacy of immune enhancement using recombinant interferon gamma1b (rIFN-gamma1b) in patients with cancer who received GTX for refractory, systemic, opportunistic infections... - Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
Blood 116:4422-9. 2010..In summary, the prognosis of most patients (72%) ? 70 years of age with AML is poor with intensive chemotherapy (8-week mortality ? 30%; median survival < 6 months)... - Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphomaApostolia Maria Tsimberidou
Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 455, Houston, TX 77030, USA
J Clin Oncol 27:904-10. 2009..The aim of this study was to determine the frequency, outcomes, and factors associated with other cancers in patients with CLL/SLL... - Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 yearsHagop Kantarjian
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
Cancer 113:1933-52. 2008..In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon... - Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring SystemHagop Kantarjian
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 113:1351-61. 2008.... - Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemiaHagop Kantarjian
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 101:2788-801. 2004..The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) program, with a median follow-up time of 63 months... - Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alphaJorge Cortes
Department of Leukemia and Bioimmunotherapy, M D Anderson Cancer Center, University of Texas Houston, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
Blood 102:83-6. 2003..In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission... - Myelodysplastic syndrome is not merely "preleukemia"Maher Albitar
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston 77030 4095, USA
Blood 100:791-8. 2002.... - Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up resultsHagop M Kantarjian
Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 8:2177-87. 2002..We identified pretreatment and treatment-associated factors that were associated with higher major cytogenetic response rates and with improved survival... - Effective cytotoxicity against human leukemias and chemotherapy-resistant leukemia cell lines by N-N-dimethylsphingosineDavid B Jendiroba
Departments of Special Medical Education Programs, Molecular and Cellular Oncology and Genitourinary Medical Oncology, Division of Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Leuk Res 26:301-10. 2002..DMS-based chemotherapy may improve leukemia treatment... - Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosisHagop M Kantarjian
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 97:1033-41. 2003.... - Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemiaHagop Kantarjian
Department of Leukemia, Anderson Cancer Center, Houston, TX, USA
Blood 102:2379-86. 2003..03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance... - Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGelHatice Duzkale
Department of Special Medical Education Programs and Adult Leukemia Research Program, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Biol Blood Marrow Transplant 9:364-72. 2003..We concluded that for acute myelogenous leukemia blasts expressing CD33, HuM195/rGel could be useful as a purging reagent for autologous transplantation... - Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 settingRazelle Kurzrock
Department of Bioimmunotherapy, Unit 422, 1515 Holcombe Blvd, Houston, TX 77030, USA
Blood 102:4527-34. 2003..09). We conclude that, at doses that are well tolerated, R115777 markedly inhibits the FTase target and has antitumor activity in MDS... - Adult acute erythroleukemia: an analysis of 91 patients treated at a single institutionF P S Santos
Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leukemia 23:2275-80. 2009..The diagnosis of AML-M6 does not impart by itself a worse prognosis, and treatment decisions on this disease should be guided by well known AML prognostic factors... - Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluationNada Orsolic
Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston 77030-4009, USA
Br J Haematol 124:727-38. 2004..These data indicate that the combination of troxacitabine and IM has significant preclinical activity in advanced CML and that clinical evaluation of this combination is warranted... - Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell linesMichael Pearlman
Departments of Leukemia and Special Medical Education Programs, M.D. Anderson Cancer Center, Unit 55, The University of Texas, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Leuk Res 27:617-26. 2003..DEX appears to be a promising drug in the treatment of AML and warrants further clinical study involving novel drug combinations... - Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986Rashid Saba
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 103:2551-7. 2005.... - MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cellsMirna Golemovic
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
Invest New Drugs 28:402-12. 2010..This agent, therefore, combines low in vivo toxicity with formidable in vitro pro-apoptotic ROS-mediated activity, and may represent a novel OAD suitable for clinical development against a variety of hematological malignancies... - Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemiaE H Estey
Department of Leukemia Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
Blood 94:2230-5. 1999..Our data suggest that lipoATRA is an effective means of producing molecular CR in newly diagnosed APL... - Can we conquer cancer in the twenty-first century?E J Freireich
Adult Leukemia Research Program, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
Cancer Chemother Pharmacol 48:S4-10. 2001..To address the question in the title of this paper, I believe that it is not a question of whether, but only of when... - Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemiaEhab Atallah
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
Blood 110:3547-51. 2007..Guidelines for reporting adverse events in leukemia studies should be revisited... - The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patientsApostolia Maria Tsimberidou
Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 14:721-30. 2008..Serum beta(2) microglobulin (beta2M) is prognostic in other hematologic malignancies; therefore, we evaluated its prognostic significance in acute myeloid leukemia (AML)... - Dexrazoxane's protection of jejunal crypt cells in the jejunum of C3Hf/Kam mice from doxorubicin-induced toxicityMichael Pearlman
Departments of Leukemia and Special Medical Educations Program-Unit 55, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
Cancer Chemother Pharmacol 52:477-81. 2003..Our findings support the use of DEX to prevent or ameliorate mucositis in patients receiving anthracycline-based therapy and the use of DEX with high-dose doxorubicin to treat refractory disease... - High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemiaA Ferrajoli
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Clin Cancer Res 7:795-9. 2001..Further studies should investigate the biological implications of these findings and the effect of the interaction between VEGF and VEGFR-2 on CLL cell proliferation... - Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemiaM J Keating
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston 77030, USA
Leuk Lymphoma 37:71-85. 2000..These models can be used to identify risk groups to guide physicians in decision-making and to assist in the design and analysis of clinical trials... - In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell linesHatice Duzkale
Department of Special Medical Education Programs, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
Cancer Chemother Pharmacol 51:427-32. 2003..However, concentrations of DMAA needed to achieve such efficacy are up to 1000 times those of As(2)O(3). Evaluation of novel organic arsenic that would combine the high efficacy of As(2)O(3) and the low toxicity of DMAA is warranted... - Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndromeAlberto J Montero
Hematology-Oncology Division, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA
Leuk Lymphoma 47:2049-54. 2006..Our study provides additional clinical evidence that chronic administration of IL-11, at low doses, can raise platelet counts and reduce platelet transfusion requirements in a subset of patients with MDS... - Influence of high-efficiency particulate air filtration on mortality and fungal infection: a rebuttalGerald Paul Bodey
J Infect Dis 194:1621-2; author reply 1622-3. 2006 - Randomization in Phase II Clinical TrialsGreg Yothers
NSABP Biostatistical Center, Pittsburgh, PA, USA
Clin Adv Hematol Oncol 4:776-8. 2006
Research Grants
- Patient-Oriented Cancer Research Training ProgramEmil Freireich; Fiscal Year: 2004..The program will prepare oncology physician specialists for careers in academic patient-oriented research in oncology. ..